Please assess the completion status of the following clinical trial:

Trial Title: A Trial of Multiple-doses of Aripiprazole in Adults With Schizophrenia or Bipolar 1 Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* A current diagnosis of schizophrenia or bipolar I disorder, as defined by Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria.~* Body mass index of 18 to 35 kilograms per meter square (kg/m\^2).~* On a stable dose of an atypical oral antipsychotic medication for at least 2 months prior to screening.~Exclusion Criteria:~* Participants who have:~  * Met DSM-5 criteria for substance use disorder within the past 180 days.~ * A positive drug screen for drugs of abuse~* Use of any psychotropic medications other than their current non-aripiprazole antipsychotic or mood stabilizer(s) medication; or participants who use more than one antipsychotic or mood stabilizer(s) medication at screening.~* Females who are pregnant, breast-feeding, lactating, and/or have a positive pregnancy test result prior to receiving investigational medicinal product (IMP). A negative serum pregnancy test must be confirmed prior to the first dose of IMP for all female participants.~* Any major surgery within 30 days prior to enrollment or scheduled/elective surgery during the trial.~* Evidence of organ dysfunction or any clinically significant deviation from normal in the physical, electrocardiographic, or clinical laboratory examinations.~* Participants currently in an acute relapse of schizophrenia.~* Participants with a current DSM-5 diagnosis other than schizophrenia or bipolar I disorder, including schizoaffective disorder, major depressive disorder, delirium, dementia, amnestic, or other cognitive disorders. Also, participants with borderline, paranoid, histrionic, or antisocial personality disorder.~* Participants with a history of neuroleptic malignant syndrome or clinically significant tardive dyskinesia.~* History of any significant drug allergy or known or suspected hypersensitivity, in particular to aripiprazole or other quinolinones.~* History of or current hepatitis or acquired immunodeficiency syndrome or carriers of Hepatitis B surface antigen (HBsAg) or Hepatitis C antibodies (anti-HCV), and/or Human immunodeficiency virus (HIV) antibodies.~* Participants deemed intolerant of receiving injections.~* Participants who have had electroconvulsive therapy within 2 months of administration of IMP.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- Aripiprazole 2M LAI 960 mg: Schizophrenia or Bipolar I Disorder (Type: EXPERIMENTAL): Participants with schizophrenia or bipolar I disorder received aripiprazole 2 month (2M) long-acting injection (LAI) 960 milligrams (mg) for a total of 4 injections administered every 56 days (± 2 days) over the course of 32 weeks.
- Aripiprazole IM Depot 400 mg: Schizophrenia or Bipolar I Disorder (Type: EXPERIMENTAL): Participants with schizophrenia or bipolar I disorder received aripiprazole IM 400 mg, for a total of 8 injections administered every 28 days (± 2 days) over the course of 32 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete